Participating in a vaccine trial for COVID-19 in Senegal: trust and information

Hum Vaccin Immunother. 2021 Nov 2;17(11):3907-3912. doi: 10.1080/21645515.2021.1951097. Epub 2021 Jul 19.


This research aims to understand the level and determinants of people's willingness to participate in a vaccine trial for COVID-19 in Senegal. We conducted a telephone survey among a marginal quota sample of 607 people over 18 years of age. Only 44.3% of the participants wanted to participate in a vaccine trial for COVID-19, with females intending to participate more than males (AOR = 1.82, 95% CI [1.22-2.72]). Participants who intended to be vaccinated against COVID-19 (AOR = 6.48, 95% CI [4.12-10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (AOR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to take part in the COVID-19 vaccine trial. Confidence in the vaccine, health personnel, and the government in the fight against the pandemic are key factors in participants' willingness to participate in a vaccine trial in Senegal.

Keywords: COVID-19; Senegal; Vaccine trial; acceptability; participation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • COVID-19 Vaccines
  • COVID-19*
  • Female
  • Humans
  • Male
  • SARS-CoV-2
  • Senegal / epidemiology
  • Trust
  • Vaccines*


  • COVID-19 Vaccines
  • Vaccines

Grants and funding

This work was supported by the Agence Française de Développement (AFD) and Institut de Recherche pour le Développement (IRD).